Oulian Biosciences (688319.SH) has released its half-year performance, with a net profit attributable to shareholders of 13.2 million yuan, turning losses into profits compared to the same period last year.

Wisdom Finance and Economics APP News, Olon Biotech (688319.SH) disclosed its semi-annual report for 2025, during the reporting period the company achieved a revenue of 306 million yuan, a year-on-year increase of 35.17%; net profit attributable to the parent company was 13.2 million yuan, turning a loss into a profit year-on-year; non-net profit was 7.72 million yuan, turning a loss into a profit year-on-year; basic earnings per share was 0.0326 yuan.